High-throughput human autoantibody discovery service.
Our new HuScan™ technology provides epitope-level antibody discovery versus the entire human proteome.
ANTYGEN™ HuScan™ service, co-developed by CDI’s Scientific Advisory Board Member Ben Larman, allows us to analyze patient samples (serum, plasma, CSF, etc.) for the presence of autoantibodies against the full UniProt human proteome in a single-well assay with quantitative sequencing readouts. This product is available as a service to both academic and industry customers.